Cargando…

Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort

The genetic polymorphisms rs2395185 and rs2097432 in HLA genes have been associated with the response to anti-TNF treatment in inflammatory bowel disease (IBD). The aim was to analyze the association between these variants and the long-term response to anti-TNF drugs in pediatric IBD. We performed a...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvador-Martín, Sara, Zapata-Cobo, Paula, Velasco, Marta, Palomino, Laura M., Clemente, Susana, Segarra, Oscar, Sánchez, Cesar, Tolín, Mar, Moreno-Álvarez, Ana, Fernández-Lorenzo, Ana, Pérez-Moneo, Begoña, Loverdos, Inés, Navas López, Victor Manuel, Millán, Antonio, Magallares, Lorena, Torres-Peral, Ricardo, García-Romero, Ruth, Pujol-Muncunill, Gemma, Merino-Bohorquez, Vicente, Rodríguez, Alejandro, Salcedo, Enrique, López-Cauce, Beatriz, Marín-Jiménez, Ignacio, Menchén, Luis, Laserna-Mendieta, Emilio, Lucendo, Alfredo J., Sanjurjo-Sáez, María, López-Fernández, Luis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861004/
https://www.ncbi.nlm.nih.gov/pubmed/36675312
http://dx.doi.org/10.3390/ijms24021797
_version_ 1784874733182910464
author Salvador-Martín, Sara
Zapata-Cobo, Paula
Velasco, Marta
Palomino, Laura M.
Clemente, Susana
Segarra, Oscar
Sánchez, Cesar
Tolín, Mar
Moreno-Álvarez, Ana
Fernández-Lorenzo, Ana
Pérez-Moneo, Begoña
Loverdos, Inés
Navas López, Victor Manuel
Millán, Antonio
Magallares, Lorena
Torres-Peral, Ricardo
García-Romero, Ruth
Pujol-Muncunill, Gemma
Merino-Bohorquez, Vicente
Rodríguez, Alejandro
Salcedo, Enrique
López-Cauce, Beatriz
Marín-Jiménez, Ignacio
Menchén, Luis
Laserna-Mendieta, Emilio
Lucendo, Alfredo J.
Sanjurjo-Sáez, María
López-Fernández, Luis A.
author_facet Salvador-Martín, Sara
Zapata-Cobo, Paula
Velasco, Marta
Palomino, Laura M.
Clemente, Susana
Segarra, Oscar
Sánchez, Cesar
Tolín, Mar
Moreno-Álvarez, Ana
Fernández-Lorenzo, Ana
Pérez-Moneo, Begoña
Loverdos, Inés
Navas López, Victor Manuel
Millán, Antonio
Magallares, Lorena
Torres-Peral, Ricardo
García-Romero, Ruth
Pujol-Muncunill, Gemma
Merino-Bohorquez, Vicente
Rodríguez, Alejandro
Salcedo, Enrique
López-Cauce, Beatriz
Marín-Jiménez, Ignacio
Menchén, Luis
Laserna-Mendieta, Emilio
Lucendo, Alfredo J.
Sanjurjo-Sáez, María
López-Fernández, Luis A.
author_sort Salvador-Martín, Sara
collection PubMed
description The genetic polymorphisms rs2395185 and rs2097432 in HLA genes have been associated with the response to anti-TNF treatment in inflammatory bowel disease (IBD). The aim was to analyze the association between these variants and the long-term response to anti-TNF drugs in pediatric IBD. We performed an observational, multicenter, ambispective study in which we selected 340 IBD patients under 18 years of age diagnosed with IBD and treated with anti-TNF drugs from a network of Spanish hospitals. Genotypes and failure of anti-TNF drugs were analyzed using Kaplan-Meier curves and Cox logistic regression. The homozygous G allele of rs2395185 and the C allele of rs2097432 were associated with impaired long-term response to anti-TNF drugs in children with IBD after 3 and 9 years of follow-up. Being a carrier of both polymorphisms increased the risk of anti-TNF failure. The SNP rs2395185 but not rs2097432 was associated with response to infliximab in adults with CD treated with infliximab but not in children after 3 or 9 years of follow-up. Conclusions: SNPs rs2395185 and rs2097432 were associated with a long-term response to anti-TNFs in IBD in Spanish children. Differences between adults and children were observed in patients diagnosed with CD and treated with infliximab.
format Online
Article
Text
id pubmed-9861004
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98610042023-01-22 Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort Salvador-Martín, Sara Zapata-Cobo, Paula Velasco, Marta Palomino, Laura M. Clemente, Susana Segarra, Oscar Sánchez, Cesar Tolín, Mar Moreno-Álvarez, Ana Fernández-Lorenzo, Ana Pérez-Moneo, Begoña Loverdos, Inés Navas López, Victor Manuel Millán, Antonio Magallares, Lorena Torres-Peral, Ricardo García-Romero, Ruth Pujol-Muncunill, Gemma Merino-Bohorquez, Vicente Rodríguez, Alejandro Salcedo, Enrique López-Cauce, Beatriz Marín-Jiménez, Ignacio Menchén, Luis Laserna-Mendieta, Emilio Lucendo, Alfredo J. Sanjurjo-Sáez, María López-Fernández, Luis A. Int J Mol Sci Article The genetic polymorphisms rs2395185 and rs2097432 in HLA genes have been associated with the response to anti-TNF treatment in inflammatory bowel disease (IBD). The aim was to analyze the association between these variants and the long-term response to anti-TNF drugs in pediatric IBD. We performed an observational, multicenter, ambispective study in which we selected 340 IBD patients under 18 years of age diagnosed with IBD and treated with anti-TNF drugs from a network of Spanish hospitals. Genotypes and failure of anti-TNF drugs were analyzed using Kaplan-Meier curves and Cox logistic regression. The homozygous G allele of rs2395185 and the C allele of rs2097432 were associated with impaired long-term response to anti-TNF drugs in children with IBD after 3 and 9 years of follow-up. Being a carrier of both polymorphisms increased the risk of anti-TNF failure. The SNP rs2395185 but not rs2097432 was associated with response to infliximab in adults with CD treated with infliximab but not in children after 3 or 9 years of follow-up. Conclusions: SNPs rs2395185 and rs2097432 were associated with a long-term response to anti-TNFs in IBD in Spanish children. Differences between adults and children were observed in patients diagnosed with CD and treated with infliximab. MDPI 2023-01-16 /pmc/articles/PMC9861004/ /pubmed/36675312 http://dx.doi.org/10.3390/ijms24021797 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Salvador-Martín, Sara
Zapata-Cobo, Paula
Velasco, Marta
Palomino, Laura M.
Clemente, Susana
Segarra, Oscar
Sánchez, Cesar
Tolín, Mar
Moreno-Álvarez, Ana
Fernández-Lorenzo, Ana
Pérez-Moneo, Begoña
Loverdos, Inés
Navas López, Victor Manuel
Millán, Antonio
Magallares, Lorena
Torres-Peral, Ricardo
García-Romero, Ruth
Pujol-Muncunill, Gemma
Merino-Bohorquez, Vicente
Rodríguez, Alejandro
Salcedo, Enrique
López-Cauce, Beatriz
Marín-Jiménez, Ignacio
Menchén, Luis
Laserna-Mendieta, Emilio
Lucendo, Alfredo J.
Sanjurjo-Sáez, María
López-Fernández, Luis A.
Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort
title Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort
title_full Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort
title_fullStr Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort
title_full_unstemmed Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort
title_short Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort
title_sort association between hla dna variants and long-term response to anti-tnf drugs in a spanish pediatric inflammatory bowel disease cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861004/
https://www.ncbi.nlm.nih.gov/pubmed/36675312
http://dx.doi.org/10.3390/ijms24021797
work_keys_str_mv AT salvadormartinsara associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT zapatacobopaula associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT velascomarta associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT palominolauram associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT clementesusana associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT segarraoscar associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT sanchezcesar associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT tolinmar associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT morenoalvarezana associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT fernandezlorenzoana associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT perezmoneobegona associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT loverdosines associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT navaslopezvictormanuel associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT millanantonio associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT magallareslorena associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT torresperalricardo associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT garciaromeroruth associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT pujolmuncunillgemma associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT merinobohorquezvicente associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT rodriguezalejandro associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT salcedoenrique associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT lopezcaucebeatriz associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT marinjimenezignacio associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT menchenluis associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT lasernamendietaemilio associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT lucendoalfredoj associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT sanjurjosaezmaria associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort
AT lopezfernandezluisa associationbetweenhladnavariantsandlongtermresponsetoantitnfdrugsinaspanishpediatricinflammatoryboweldiseasecohort